Clinical Trial

Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated November 22, 2023 (before its estimated September 30, 2024 completion). Its status may not reflect the trial's current state.
Summary
To compare the pathological efficacy of neoadjuvant Toripalimab and Albumin paclitaxel /Cisplatin (TTP) with Docetaxel/ Cisplatin/ 5-flurouracil (TPF) for patients with locally advanced resectable oral squamous cell carcinoma (OSCC), and to determine the safety of neoadjuvant TTP. In order to explore a better protocol of neoadjuvant therapy to improve the efficacy in patients with locally advanced OSCC.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2021-11-17; most recent amendment 2023-11-21.
Trial Details
NCT Number NCT05125055
Lead Sponsor Shanghai Jiao Tong University School of Medicine
Conditions Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1, Chemotherapy
Enrollment 80 participants
Start Date 2021-10-01
Primary Completion 2024-09-30 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2023-11-22